Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
fold decrease » fold increased (Expand Search), fold increases (Expand Search), fid decreased (Expand Search)
increase » increased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
fold decrease » fold increased (Expand Search), fold increases (Expand Search), fid decreased (Expand Search)
increase » increased (Expand Search)
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
Key biological processes and genes are identified in TGF-β1-induced fibrosis via transcriptome analysis.
Published 2024“…<b>(A)</b> Differentially expressed genes (DEGs; ≥2 folds, ≥7 normalized data value) significantly altered by TGF-β1 treatment were depicted by a Venn diagram. …”
-
189
Data Sheet 3_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.docx
Published 2025“…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
-
190
Data Sheet 2_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.docx
Published 2025“…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
-
191
Data Sheet 1_Changes in monocyte subsets are associated with an increased risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease.pdf
Published 2025“…A decrease in classical monocytes [odds ratio (OR): 0.73, p = 0.002] and increases in intermediate (OR: 1.41, p = 0.006) and non-classical monocytes (OR: 1.54, p = 0.030) were associated with a higher risk of AAA. …”
-
192
-
193
Validation of model predictions of growth during infusion of hypertrophic agonists with and without receptor blockers.
Published 2025“…By contrast, the model prediction of nearly equal likelihood that ERA increases or decreases NE-induced growth appears to contradict a significant reported decrease in the only available experimental study [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1012390#pcbi.1012390.ref121" target="_blank">121</a>]. …”
-
194
-
195
-
196
Development of a User-Friendly Dynamic Culture System for Decellularized Scaffold-Based Tissue Engineering
Published 2025“…Compared to static controls, constructs cultured in our platform exhibited a > 5-fold increase in proliferating (Ki67+) cells and a 32-fold decrease in apoptotic (TUNEL+) cells. …”
-
197
-
198
Minimal data set.
Published 2025“…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”
-
199
Fragmentation patterns for Schisandrin A.
Published 2025“…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”
-
200
Chemical structure of a lignan.
Published 2025“…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”